Enliven Therapeutics (Enliven Therapeutics) EBIT per Share : $-2.25 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics EBIT per Share?

Enliven Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.62. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.25.

During the past 3 years, the average EBIT per Share Growth Rate was -117.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Enliven Therapeutics's EBIT per Share or its related term are showing as below:

ELVN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -117.9 Med: -117.9 Max: -117.9
Current: -117.9

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Enliven Therapeutics was -117.90% per year. The lowest was -117.90% per year. And the median was -117.90% per year.

ELVN's 3-Year EBIT Growth Rate is ranked worse than
97.47% of 1303 companies
in the Biotechnology industry
Industry Median: 3.6 vs ELVN: -117.90

Enliven Therapeutics's EBIT for the three months ended in Mar. 2024 was $-25.99 Mil.

Enliven Therapeutics EBIT per Share Historical Data

The historical data trend for Enliven Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics EBIT per Share Chart

Enliven Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.23

-0.60

-0.94

-2.35

Enliven Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial							-0.89	-0.49	-0.59	-0.55	-0.62

Enliven Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Enliven Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-83.529	/	35.546
=	-2.35

Enliven Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.987	/	42.046
=	-0.62

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.25

Enliven Therapeutics (NAS:ELVN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Enliven Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Enliven Therapeutics (Enliven Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

6200 Lookout Road, Boulder, CO, USA, 80301

Website

https://www.enliventherapeutics.com

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.

Executives

Anish Patel	officer: Chief Operating Officer	C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Benjamin Hohl	officer: Chief Financial Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Joseph P Lyssikatos	director, officer: Chief Scientific Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz	director, officer: President and CEO	ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Richard A. Heyman	director	5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Andrew J. Schwab	director	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jake Bauer	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vi, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Enliven Therapeutics (Enliven Therapeutics) Headlines

From GuruFocus

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

By sperokesalga sperokesalga • 05-31-2023

Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares

By GuruFocus Research • 01-03-2024

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

By Marketwired • 08-10-2023

Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga • 05-11-2023